Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study

Ítems similars

• Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations
  per: Ramakrishnan, Jaganathan, et al.
  Publicat: (2021)
• In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
  per: Khater, Ibrahim, et al.
  Publicat: (2021)
• A molecular docking study of potential inhibitors and repurposed drugs against SARS-CoV-2 main protease enzyme()
  per: Ercan, Selami, et al.
  Publicat: (2021)
• In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing
  per: Kumar, Yogesh, et al.
  Publicat: (2020)
• Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M(pro) Protease
  per: Tejera, Eduardo, et al.
  Publicat: (2020)